RU2107497C1 - Противоаллергическая фармацевтическая композиция для местного глазного применения и способ ее получения - Google Patents
Противоаллергическая фармацевтическая композиция для местного глазного применения и способ ее получения Download PDFInfo
- Publication number
- RU2107497C1 RU2107497C1 RU94016184A RU94016184A RU2107497C1 RU 2107497 C1 RU2107497 C1 RU 2107497C1 RU 94016184 A RU94016184 A RU 94016184A RU 94016184 A RU94016184 A RU 94016184A RU 2107497 C1 RU2107497 C1 RU 2107497C1
- Authority
- RU
- Russia
- Prior art keywords
- amount
- production
- formula
- pharmaceutical composition
- ige
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 10
- 230000003266 anti-allergic effect Effects 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 239000003889 eye drop Substances 0.000 claims description 21
- 229940012356 eye drops Drugs 0.000 claims description 21
- 230000000699 topical effect Effects 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 13
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- 230000016784 immunoglobulin production Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 2
- 239000000945 filler Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 description 22
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 18
- 239000002997 ophthalmic solution Substances 0.000 description 15
- 229940054534 ophthalmic solution Drugs 0.000 description 14
- 229950001956 suplatast Drugs 0.000 description 14
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- DYZJXZOQQRXDLE-UHFFFAOYSA-O Suplatast tosilate Chemical compound CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 DYZJXZOQQRXDLE-UHFFFAOYSA-O 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003885 eye ointment Substances 0.000 description 6
- 229950011082 suplatast tosilate Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 229940069265 ophthalmic ointment Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 208000030961 allergic reaction Diseases 0.000 description 4
- 239000000043 antiallergic agent Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- -1 etc.) Chemical compound 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DUDKKPVINWLFBI-UHFFFAOYSA-N 1-chlorobut-1-ene Chemical compound CCC=CCl DUDKKPVINWLFBI-UHFFFAOYSA-N 0.000 description 1
- LVZIWKFQFKNSMO-UHFFFAOYSA-N 1-chlorobutan-1-ol Chemical compound CCCC(O)Cl LVZIWKFQFKNSMO-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- YEFLBBKGKYISGL-UHFFFAOYSA-N n-[4-(3-ethoxy-2-hydroxypropoxy)phenyl]-3-methylsulfanylpropanamide Chemical compound CCOCC(O)COC1=CC=C(NC(=O)CCSC)C=C1 YEFLBBKGKYISGL-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- IJVQLFVNQUBHES-UHFFFAOYSA-N triethyl pyridine-2,4,6-tricarboxylate Chemical compound CCOC(=O)C1=CC(C(=O)OCC)=NC(C(=O)OCC)=C1 IJVQLFVNQUBHES-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 231100000691 up-and-down procedure Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11279593 | 1993-05-14 | ||
| JP112795/93 | 1993-05-14 | ||
| JP112795/1993 | 1993-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU94016184A RU94016184A (ru) | 1996-05-20 |
| RU2107497C1 true RU2107497C1 (ru) | 1998-03-27 |
Family
ID=14595714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU94016184A RU2107497C1 (ru) | 1993-05-14 | 1994-05-12 | Противоаллергическая фармацевтическая композиция для местного глазного применения и способ ее получения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5475033A (enExample) |
| EP (1) | EP0624367A1 (enExample) |
| KR (1) | KR0160538B1 (enExample) |
| CN (1) | CN1103782A (enExample) |
| AU (1) | AU679043B2 (enExample) |
| BR (1) | BR9401965A (enExample) |
| CA (1) | CA2123367C (enExample) |
| HU (1) | HUT70749A (enExample) |
| PL (1) | PL175375B1 (enExample) |
| RU (1) | RU2107497C1 (enExample) |
| TW (1) | TW264385B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2238088C1 (ru) * | 2003-10-02 | 2004-10-20 | Государственное предприятие Институт иммунологии Федерального управления медико-биологических и экстремальных проблем при Министерстве здравоохранения РФ | N, n-диэтилдитиокарбаминовой кислоты натриевая соль, обладающая противоаллергическим действием |
| WO2013188217A1 (en) * | 2012-06-11 | 2013-12-19 | Macuclear, Inc. | Therapeutic formulation and methods of treatment |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996033741A1 (en) * | 1995-04-24 | 1996-10-31 | Taiho Pharmaceutical Co., Ltd. | Remedy for allergic diseases in the region of the nose |
| RU2123327C1 (ru) * | 1996-05-27 | 1998-12-20 | Вилен Гургенович Петросян | Капли петросяна n 1 (n 2 - n 7 их варианты) для лечения аллергических и неатопических заболеваний глаз и носа |
| RU2123840C1 (ru) * | 1996-05-27 | 1998-12-27 | Петросян Вилен Гургенович | Капли петросяна n 1a (n 2a - n 7a их варианты) для лечения аллергических и неатопических заболеваний глаз и носа |
| RU2123839C1 (ru) * | 1996-05-27 | 1998-12-27 | Вилен Гургенович Петросян | Капли петросяна n 1б (2б-7б их варианты) для лечения аллергических и неатопических заболеваний глаз и носа |
| CN1224384C (zh) * | 1998-11-05 | 2005-10-26 | 大鹏药品工业株式会社 | 用于治疗排尿紊乱的治疗药物 |
| DK1295870T3 (da) * | 2001-04-16 | 2008-01-28 | Taiho Pharmaceutical Co Ltd | Suplatasttosilatkrystaller |
| EP1387696A2 (en) * | 2001-05-03 | 2004-02-11 | Novartis AG | Anti-ige antibody to treat ocular allergies |
| WO2010141883A1 (en) * | 2009-06-04 | 2010-12-09 | The Regents Of The University Of Colorado | Compounds that modulate autoimmunity and methods of using the same |
| WO2012162697A1 (en) | 2011-05-26 | 2012-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Compounds that modulate autoimmunity and methods of using the same |
| EP3247384B1 (en) | 2015-01-14 | 2023-10-04 | The Regents of the University of Colorado, a body corporate | In vitro method of diagnosis of type 1 diabetes with insulin mimotopes |
| EP3432877B1 (en) | 2016-03-24 | 2023-01-11 | ImmunoMolecular Therapeutics, Inc. | D-alpha-methyldopa for treating autoimmune disease |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2523976B1 (fr) * | 1982-03-26 | 1985-08-30 | Pasteur Institut | Nouveau produit proteique, obtention et application comme medicament, en particulier immunoregulateur et antiallergique |
| US4556737A (en) * | 1983-03-11 | 1985-12-03 | Taiho Pharmaceutical Company Limited | Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same |
| US4691018A (en) * | 1985-05-23 | 1987-09-01 | Chugai Seiyaku Kabushiki Kaisha | Pyridine derivatives and their use as anti-allergic agents |
| US5157052A (en) * | 1990-12-27 | 1992-10-20 | Monsanto Company | Method for inhibiting ige production |
| KR950012657B1 (en) * | 1991-01-22 | 1995-10-19 | Nec Co Ltd | Resin sealed semiconductor integrated circuit |
-
1994
- 1994-04-30 TW TW083103913A patent/TW264385B/zh active
- 1994-05-06 AU AU61934/94A patent/AU679043B2/en not_active Ceased
- 1994-05-06 HU HU9401434A patent/HUT70749A/hu unknown
- 1994-05-11 CA CA002123367A patent/CA2123367C/en not_active Expired - Fee Related
- 1994-05-12 BR BR9401965A patent/BR9401965A/pt not_active Application Discontinuation
- 1994-05-12 US US08/241,719 patent/US5475033A/en not_active Expired - Fee Related
- 1994-05-12 RU RU94016184A patent/RU2107497C1/ru active
- 1994-05-12 PL PL94303428A patent/PL175375B1/pl unknown
- 1994-05-13 EP EP94303452A patent/EP0624367A1/en not_active Withdrawn
- 1994-05-13 CN CN94105811A patent/CN1103782A/zh active Pending
- 1994-05-14 KR KR1019940010571A patent/KR0160538B1/ko not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| US, N 4556737, (Taiho Pharmacentical Comp. Ltd), кл. C 07C103/12, 1985. WO, N 8906130 (Santen Pharmacentical Co, Ltd.), кл. A 61K 31/495, 1989. SU, 1804838 А1 (Всесоюзный НИИ фармации), кл. A 61K 9/08, 1993. * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2238088C1 (ru) * | 2003-10-02 | 2004-10-20 | Государственное предприятие Институт иммунологии Федерального управления медико-биологических и экстремальных проблем при Министерстве здравоохранения РФ | N, n-диэтилдитиокарбаминовой кислоты натриевая соль, обладающая противоаллергическим действием |
| WO2013188217A1 (en) * | 2012-06-11 | 2013-12-19 | Macuclear, Inc. | Therapeutic formulation and methods of treatment |
| US9254287B2 (en) | 2012-06-11 | 2016-02-09 | Macuclear, Inc. | Therapeutic formulation and methods of treatment |
| US9694010B2 (en) | 2012-06-11 | 2017-07-04 | Macuclear, Inc. | Therapeutic formulation and methods of treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| TW264385B (enExample) | 1995-12-01 |
| HUT70749A (en) | 1995-10-30 |
| CA2123367A1 (en) | 1994-11-15 |
| RU94016184A (ru) | 1996-05-20 |
| AU679043B2 (en) | 1997-06-19 |
| AU6193494A (en) | 1994-11-17 |
| BR9401965A (pt) | 1994-12-13 |
| PL175375B1 (pl) | 1998-12-31 |
| CA2123367C (en) | 1998-04-14 |
| HU9401434D0 (en) | 1994-08-29 |
| CN1103782A (zh) | 1995-06-21 |
| EP0624367A1 (en) | 1994-11-17 |
| US5475033A (en) | 1995-12-12 |
| KR0160538B1 (ko) | 1998-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2107497C1 (ru) | Противоаллергическая фармацевтическая композиция для местного глазного применения и способ ее получения | |
| US5114917A (en) | Treatment of inflammation using alpha 1-antichymotrypsin | |
| CA2019974C (en) | Treatment of inflammation | |
| CA2104196C (en) | Methods of combating pneumocystis carinii pneumonia and compounds useful therefor | |
| JP2746832B2 (ja) | 眼局所抗アレルギー剤 | |
| US5716952A (en) | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists | |
| US5438060A (en) | Method of reducing elevated intraocular pressure | |
| HU215959B (hu) | Eljárás 5-metil-izoxazol-4-karbonsav-anilideket vagy 2-hidroxi-etilidén ciano-ecetsav-anilideket tartalmazó, szembetegségek kezelésére helyileg alkalmazható gyógyszerkészítmények előállítására | |
| EP0399051A1 (en) | Polyvalent antiinflammatory agent | |
| KR100596136B1 (ko) | 소형 펩타이드 및 천식 및 염증을 치료하기 위한 방법 | |
| US6077839A (en) | Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists | |
| US10548870B2 (en) | Method for treating multiple sclerosis | |
| US5886045A (en) | Remedy for allergic diseases in the region of the nose | |
| JPH06329538A (ja) | 皮膚疾患処置用薬剤 | |
| JP2001519394A (ja) | 緑内障の局所治療用フルナリジンの使用法 | |
| KR20040077800A (ko) | 부나조신 및 프로스타글란딘을 포함하는 녹내장 치료제 | |
| US4348407A (en) | Orally active tolciclate and tolnaftate | |
| JP2003292442A (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
| RU2180842C2 (ru) | Способ регуляторного воздействия на первичные механизмы основных защитных реакций организма в норме и патологии: иммунной реакции, воспалительной реакции, свободнорадикального процесса, - с помощью вещества гамма-глутамилгистамин | |
| CA2379778A1 (en) | 2-aminotetralin derivatives for the therapy of glaucoma | |
| USRE32145E (en) | Orally active tolciclate .[.(and tolnaftate).]. | |
| JPH08183734A (ja) | 内毒素ショックの処置へのカルニチンおよびアルカノイルカルニチン類のフタリジリデンエステル類の使用 | |
| JPH0624978A (ja) | 抗アレルギー剤 | |
| PT96703A (pt) | Processo de preparacao de composicoes farmaceuticas a base de derivados de acido 6-n-butil-1,4,7,1o-tetra-hidro-4,1o-dioxo-1,7-fenantrolina-2,8-dicarboxilico | |
| JPS6253922A (ja) | 腎炎予防・治療剤 |